ClariSIGMAM

by ClariPi Inc.  · Based in South Korea → — Innovative solutions for the unmet needs in medical imaging fields
Oncology Radiology

Affordable cost
Regulatory Status Disclosed

Overview

ClariSIGMAM by ClariPi is an innovative AI-powered software solution designed for accurate and consistent breast density assessment from standard digital mammograms. Utilizing novel deep learning technology, it precisely analyzes fat and glandular tissue composition, providing quantitative breast density measurements. This fully automated system streamlines the workflow for radiologists, offering objective and consistent clinical decision-making support.

The software is fully compliant with DICOM standards, ensuring compatibility with various digital mammography and PACS systems. It simplifies compliance with breast density notification laws and aids in predicting breast cancer risk by presenting confidence levels with a color overlay on mammograms. ClariSIGMAM assesses breast density and generates breast density group information (BI-RADS A+B as fatty and BI-RADS C+D as dense) in accordance with the American College of Radiology’s BI-RADS density classification scale, outputting these metrics as DICOM structured reports or secondary captures.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Precisely analyzes fat and glandular tissue composition in mammography with deep learning technology.
  • Fully automated quantification of Breast Area, Glandular Area, and Percent Density.
  • Provides accurate and consistent density estimates from standard digital mammograms.
  • Fully compliant with DICOM: Compatible with all digital mammography and PACS systems.
  • Simplifies compliance with breast density notification laws.
  • Helps predict breast cancer risk by presenting confidence with color overlay on mammogram.
  • Outputs breast density metrics and BI-RADS classification (A+B as fatty, C+D as dense).
  • Standalone software application.
  • Simple installation and fast operation via GPU computer.
  • Compatible with multi-vendor FFDM scanners.

Use Cases

  • Automated breast density assessment in mammography.
  • Supporting breast cancer risk prediction.
  • Aiding radiologists in objective assessment of breast tissue composition.
  • Facilitating compliance with breast density notification laws.
  • Seamless integration into existing digital mammography and PACS workflows.

What Physicians Need to Know

Key Capabilities
ClariSIGMAM is an AI-powered breast density assessment solution that provides accurate and consistent density estimates from standard digital mammograms. It utilizes novel deep learning technology for fully automated quantification of breast and mammary area and proportion density measurements. The tool precisely analyzes fat and glandular tissue composition in mammography. It also generates a breast density grade in line with the American College of Radiology's BI-RADS density classification scales. [3, 5, 9]
Clinical Utility
ClariSIGMAM helps in identifying lung and breast tissue and is a breast cancer prediction marker. [2, 5] Quantitative breast density is a key indicator in breast cancer screening and diagnosis. [5] The tool aims to improve the consistency of clinical decision-making. [5] It also simplifies compliance with breast density notification laws. [5]
Integration Options
ClariSIGMAM is fully compliant with DICOM standards, allowing seamless integration with digital mammography and PACS systems. [5, 7] It is compatible with multi-vendor Full Field Digital Mammography (FFDM) scanners. [5]
Compliance Status
ClariSIGMAM is FDA cleared and CE marked. [9, 13]
Pricing Model
The pricing model for ClariSIGMAM includes a one-time license fee and subscription options. Pricing can be based on the number of analyses or installations. [3]
User Experience
ClariSIGMAM offers a convenient and smart workflow with fully automated operation, requiring no separate operator. [5] It provides a unique color-overlaid report for easy verification of AI-predicted tissue types, allowing radiologists to intuitively accept or adjust density recommendations. [5]
Implementation Complexity
ClariSIGMAM offers simple installation and fast operation via a GPU computer. [5]
Evidence Base
ClariSIGMAM's reliability is confirmed in published papers. [5] The product was developed through long-term collaborative research between engineering and medical experts. [6, 10]
Physician Tip

ClariSIGMAM can significantly enhance breast density assessment by providing automated, consistent, and objective quantification from standard digital mammograms. The AI's ability to precisely analyze tissue composition and generate BI-RADS compliant density grades can aid in more accurate risk prediction for breast cancer. The color-overlaid reports facilitate quick verification and allow for intuitive adjustments, fostering a collaborative workflow between AI and expert readers. Its DICOM compliance ensures smooth integration into existing radiology workflows. Physicians should leverage the tool's ability to simplify compliance with breast density notification laws and consider its potential to improve the consistency of clinical decision-making. [3, 5, 9]

ClariSIGMAM is designed for seamless integration into existing radiology infrastructure. Its full DICOM compliance ensures compatibility with all digital mammography and PACS systems. The software also supports multi-vendor FFDM scanners, making it adaptable to diverse clinical environments. [5, 7]

Details

Category Oncology AI, Radiology & Imaging AI
Pricing Affordable cost
DeploymentCan be a standalone solution running from a desktop PC or be built into different modalities such as CT machines and PACS system. Also supports cloud-based distribution and deployment. [2]
Compliance
BAA AvailableUnknown
HIPAA CompliantUnknown
FDA Status Cleared AI-estimated
Integrations
EHR Not specified
Specialties Oncology, Radiology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2021-09-10K203785 510(k)ClariSIGMAM

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate ClariSIGMAM

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money
No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for ClariSIGMAM.

View all on YouTube

Frequently Asked Questions

ClariSIGMAM is a breast density assessment solution that provides accurate and consistent density estimates from standard digital mammograms. It uses novel deep learning technology for fully automated quantification of breast and mammary area and proportion density measurements. This helps physicians in breast cancer screening and diagnosis by providing a key indicator for risk and simplifying compliance with breast density notification laws.
ClariSIGMAM is fully compliant with DICOM, making it compatible with all digital mammography and PACS systems. It operates automatically, requiring no separate operator, and is compatible with multi-vendor FFDM scanners. The system is designed for simple installation and fast operation via a GPU computer, ensuring a convenient and smart workflow.
While AI tools offer significant potential, limitations in oncology include inconsistent performance after deployment, potential for "hallucinations" or incorrect information, and biases in datasets that may affect accuracy for diverse patient populations. Additionally, integrating AI into existing clinical workflows can be challenging due to technical infrastructure limitations and the "black box" nature of some AI models, which can make it difficult for physicians to explain decisions to patients.
Several AI tools exist for oncology decision support and risk assessment. For breast cancer risk, Clairity Breast is an AI-based risk assessment tool that analyzes mammograms to predict future 5-year breast cancer risk. Other general oncology AI tools include IBM Watson for Oncology for treatment recommendations, Tempus for genomic analysis and personalized treatment, and platforms like EvidenceMD for literature and guideline synthesis.
ClariSIGMAM is CE marked, indicating its compliance with European regulatory standards. It is also fully compliant with DICOM, which facilitates its integration and use within existing medical imaging infrastructures while adhering to data exchange standards.
ClariSIGMAM employs a collaborative approach where deep learning provides its confidence with a color overlay on the mammogram. This allows readers (physicians) to intuitively accept or adjust the density recommendation. A unique color-overlaid report enables easy verification of the AI-predicted tissue types, ensuring that the final assessment benefits from both AI precision and expert human review.
ClariSIGMAM is described as having an "affordable cost" and offers a convenient and smart workflow. However, specific pricing models, tiers, or subscription options are not publicly detailed.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

More from ClariPi

ClariCT.AI
ClariPi Inc.
Radiology & Imaging AI
ClariCT.
ClariPulmo
ClariPi Inc.
Oncology AI
ClariPulmo is a non-invasive image analysis software for use with CT images which is intended to support the quantification of lung CT images. The software is designed to support the physician in the diagnosis and documentation of pulmonary tissue images (e.g., abnormalities) from the CT thoracic datasets.

View company profile →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-05 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.